Volume 353, Issue 11 2000027
FULL PAPER

Design, synthesis, and biological evaluation of new pyrazoloquinazoline derivatives as dual COX-2/5-LOX inhibitors

Mohamed A. Shaaban

Mohamed A. Shaaban

Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Search for more papers by this author
Aliaa M. Kamal

Aliaa M. Kamal

Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Department of Organic Chemistry, Faculty of Pharmacy, October University for Modern Science and Arts (MSA), Giza, Egypt

Search for more papers by this author
Samar I. Faggal

Samar I. Faggal

Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Search for more papers by this author
Nahla A. Farag

Corresponding Author

Nahla A. Farag

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Misr International University, Cairo, Egypt

Correspondence Khaled O. Mohamed, Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, 33 Kasr El-Aini Street, Cairo 11562, Egypt.

Email: [email protected]

Nahla A. Farag, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Misr International University, Km 28 Cairo-Ismailia Road (Ahmed Orabi District), Cairo 11431, Egypt.

Email: [email protected]

Search for more papers by this author
Nora M. Aborehab

Nora M. Aborehab

Department of Biochemistry, Faculty of Pharmacy, October University for Modern Science and Arts (MSA), Giza, Egypt

Search for more papers by this author
Ayman E. Elsahar

Ayman E. Elsahar

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Search for more papers by this author
Khaled O. Mohamed

Corresponding Author

Khaled O. Mohamed

Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Correspondence Khaled O. Mohamed, Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, 33 Kasr El-Aini Street, Cairo 11562, Egypt.

Email: [email protected]

Nahla A. Farag, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Misr International University, Km 28 Cairo-Ismailia Road (Ahmed Orabi District), Cairo 11431, Egypt.

Email: [email protected]

Search for more papers by this author
First published: 21 July 2020
Citations: 25

Abstract

A new series of pyrazoloquinazoline derivatives equipped with different chalcones was designed, synthesized, and identified through 1H nuclear magnetic resonance (NMR), 13C NMR, and infrared spectroscopic techniques. Our design strategy of the quinazolinone-privileged scaffold as a new scaffold was based on merging pharmacophores previously reported to exhibit cyclooxygenase-2 (COX-2)/5-lipoxygenase (5-LOX) inhibitory activity. All the newly synthesized derivatives were biologically evaluated for COX and 5-LOX inhibitory activity and COX-2 selectivity, using celecoxib and zileuton as reference drugs, as they exhibited promising anti-inflammatory activity. Compound 3j was found to be the most promising derivative, with IC50 values of 667 and 47 nM against COX-1 and COX-2, respectively, which are superior to that of celecoxib (IC50 value against COX-2 = 95 nM), showing an SI of 14.2 that was much better than celecoxib. Compounds 3f and 3h exhibited COX-1 inhibition, with IC50 values of 1,485 and 684 nM, respectively. The synthesized compounds showed a significant inhibitory activity against 5-LOX, with IC50 values ranging from 0.6 to 4.3 µM, where compounds 3f and 3h were found to be the most potent derivatives, with IC50 values of 0.6 and 1.0 µM, respectively, in comparison with that of zileuton (IC50 = 0.8 µM). These promising derivatives, 3f, 3h, and 3j, were further investigated in vivo for anti-inflammatory, gastric ulcerogenic effects, and prostaglandin production (PGE2) in rat serum. The molecular docking studies concerning the binding sites of COX-2 and 5-LOX revealed similar orientation, compared with reported inhibitors, which encouraged us to design new leads targeting COX-2 and 5-LOX as dual inhibitors, as a new avenue in anti-inflammatory therapy.

CONFLICTS OF INTERESTS

The authors declare that there are no conflicts of interests.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.